All In Biotech

Drug Trial Radar · NCT00541047

RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery

Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS)

Last checked: Nov 19, 2026Latest source record: Nov 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 4,236 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,236

Actual

Start

Nov 2007

Primary completion

Jul 27, 2022

Study completion Jul 27, 2022

Sponsor

Lead sponsor
University College, LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Canadian Cancer Trials Group
First posted
Oct 8, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 0 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy, such as goserelin, leuprolide, or bicalutamide, may lessen the amount of androgens made by the body. Giving radiation therapy together with androgen deprivation therapy may kill more prostate cancer cells. PURPOSE: This randomized phase III trial is studying how well giving radiation therapy together with androgen deprivation therapy works in treating patients who have undergone surgery for prostate cancer.

Conditions

  • Gastrointestinal Complications
  • Prostate Cancer
  • Sexual Dysfunction
  • Urinary Complications

Interventions

  • bicalutamideDrug

  • goserelin acetateDrug

  • leuprolide acetateDrug

  • adjuvant therapyProcedure

  • quality-of-life assessmentProcedure

  • radiation therapyRadiation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-specific survival (i.e., death due to prostate cancer) (RADICALS-HD)Time frame: up 12 years
  2. Freedom from distant metastases (any distance metastases or prostate cancer death) (RADICALS-RT)Time frame: up 12 years

Locations

58 sites in 2 countries. Site status is shown where the registry gives one.

  • British Columbia Cancer Agency - Centre for the Southern Interior

    Kelowna, British Columbia, Canada

  • British Columbia Cancer Agency - Vancouver Cancer Centre

    Vancouver, British Columbia, Canada

  • London Regional Cancer Program at London Health Sciences Centre

    London, Ontario, Canada

  • Ottawa Health Research Institute

    Ottawa, Ontario, Canada

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • William Harvey Hospital

    Ashford, England, United Kingdom

  • North Devon District Hospital

    Barnstaple, England, United Kingdom

  • Basingstoke and North Hampshire NHS Foundation Trust

    Basingstoke, England, United Kingdom

  • Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust

    Birmingham, England, United Kingdom

  • Royal Bournemouth Hospital

    Bournemouth, England, United Kingdom

  • Bradford Royal Infirmary

    Bradford, England, United Kingdom

  • Southmead Hospital

    Bristol, England, United Kingdom

  • Bristol Haematology and Oncology Centre

    Bristol, England, United Kingdom

  • Addenbrooke's Hospital

    Cambridge, England, United Kingdom

  • Kent and Canterbury Hospital

    Canterbury, England, United Kingdom

  • Walsgrave Hospital

    Coventry, England, United Kingdom

  • Mid Cheshire Hospitals Trust- Leighton Hopsital

    Crewe, England, United Kingdom

  • Mayday University Hospital

    Croydon, England, United Kingdom

  • Doncaster Royal Infirmary

    Doncaster, England, United Kingdom

  • Dorset County Hospital

    Dorchester, England, United Kingdom

  • Royal Devon and Exeter Hospital

    Exeter, England, United Kingdom

  • St. Luke's Cancer Centre at Royal Surrey County Hospital

    Guildford, England, United Kingdom

  • Princess Alexandra Hospital

    Harlow, England, United Kingdom

  • Ipswich Hospital

    Ipswich, England, United Kingdom

  • Leeds Cancer Centre at St. James's University Hospital

    Leeds, England, United Kingdom

  • Lincoln County Hospital

    Lincoln, England, United Kingdom

  • Helen Rollason Cancer Care Centre at North Middlesex Hospital

    London, England, United Kingdom

  • University College Hospital

    London, England, United Kingdom

  • Guy's Hospital

    London, England, United Kingdom

  • Royal Marsden - London

    London, England, United Kingdom

  • Maidstone Hospital

    Maidstone, England, United Kingdom

  • Clatterbridge Centre for Oncology

    Manchester, England, United Kingdom

  • Christie Hospital

    Manchester, England, United Kingdom

  • James Cook University Hospital

    Middlesbrough, England, United Kingdom

  • Mount Vernon Cancer Centre at Mount Vernon Hospital

    Northwood, England, United Kingdom

  • Derriford Hospital

    Plymouth, England, United Kingdom

  • Dorset Cancer Centre

    Poole Dorset, England, United Kingdom

  • Queen's Hospital

    Romford, England, United Kingdom

  • Rotherham General Hospital

    Rotherham, England, United Kingdom

  • Hope Hospital

    Salford, England, United Kingdom

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.